Price T Rowe Associates Inc Zymeworks Inc. Transaction History

Price T Rowe Associates Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.0 - $16.98 $10.3 Million - $29.1 Million	-1,714,905 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $267,222 - $515,973	17,592 Added 1.04%	1,714,905 $28.1 Million
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $17.7 Million - $24.1 Million	647,666 Added 61.7%	1,697,313 $49.3 Million
Q2 2021 Aug 16, 2021	SELL	$26.5 - $38.23 $3.61 Million - $5.21 Million	-136,150 Reduced 11.48%	1,049,647 $36.4 Million
Q1 2021 May 17, 2021	SELL	$29.83 - $56.81 $150,999 - $287,572	-5,062 Reduced 0.43%	1,185,797 $37.4 Million
Q4 2020 Feb 16, 2021	BUY	$39.12 - $54.99 $46.6 Million - $65.5 Million	1,190,859 New	1,190,859 $56.3 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $766M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.